ORION CORPORATION PRESS RELEASE 8 JUNE 2021 AT 8.00 a.m. EEST
Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy
Cancer immunotherapies, with CAR T-cell therapy as one form of therapy, have introduced entirely new possibilities for cancer treatment. In CAR T-cell therapy, the patient's own white blood cells are genetically modified to attack the cancer and kill it. CAR T-cells are currently used to treat certain haematological cancers.
The first T-cell therapies received marketing authorisation in the
The Blood Service has considerable experience in cell research, in the supply of cord blood and stem cell grafts classified as tissue products, and in the preparation of ATMP cell products classified as medicinal products. The Blood Service also has expertise and the necessary clean rooms for the research and high-quality production of therapeutic cells.
Orion has a solid research infrastructure and has introduced several proprietary drugs to the market in different therapy areas. Orion's oncology therapy area researches and develops novel proprietary drugs for the treatment of cancer. In recent years, Orion has expanded its research activities to include immuno-oncology therapies.
New possibilities for cancer treatment
The research collaboration is based on new innovations to improve the structure of the CAR T-cell product.
“Targeted immunotherapy has opened up entirely new possibilities for the treatment of cancer, and it is important to advance this development in
Project managers Satu Juhila from Orion and
Finnish Red Cross Blood Service
The Finnish Red Cross Blood Service is the nationwide blood service provider in
Further information:
Outi Vaarala
Senior Vice President, Research and Development,
Tel. +358 10 426 3472
outi.vaarala@orionpharma.com
Contact person for the media:
Terhi Ormio
Vice President, Communications,
Tel. +358 50 966 4646
terhi.ormio@orion.fi
Finnish
Finnish
Tel. +358 50 396 9450
matti.korhonen@veripalvelu.fi
Contact person for the media:
Finnish
Tel. +358 40 523 7451
willy.toiviainen@veripalvelu.fi
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
Homepage: www.orion.fi/en
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to
© OMX, source